Cochrane · systematic review · CD010631
Chlorpromazine versus atypical antipsychotic drugs for schizophrenia
Saha, KB, Bo, L, Zhao, S, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
SchizophreniaAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
16
current version
GRADE rated
16
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 11 · 68.8%Low 3 · 18.8%Moderate 2 · 12.5%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
CHLORPROMAZINE versus OLANZAPINE for schizophrenia
Population: people with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
No significant clinical response: short term (up to 6 months) CHLORPROMAZINE vs OLANZAPINE | RR 2.34 [1.37, 3.99] | 3 studies · 204 participants | Low Downgraded: risk of bias, publication bias |
Relapse: long term (over 12 months) CHLORPROMAZINE vs OLANZAPINE | RR 1.5 [0.46, 4.86] | 1 study · 70 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Mental state: short term (up to 6 months) BRPS average endpoint score (high = poor) CHLORPROMAZINE vs OLANZAPINE | no estimate extracted | 4 studies · 245 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness, publication bias |
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) CHLORPROMAZINE vs OLANZAPINE | RR 34.47 [4.79, 248.3] | 2 studies · 298 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Quality of life: short term (up to 6 months) GQOLI‐physical health subscale score (high = good) CHLORPROMAZINE vs OLANZAPINE | no estimate extracted | 1 study · 61 participants | Very low Downgraded: risk of bias, imprecision, indirectness, publication bias |
Leaving the study early due to any reason: short term (up to 6 months) CHLORPROMAZINE vs OLANZAPINE | RR 1.69 [0.45, 6.4] | 3 studies · 139 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
CHLORPROMAZINE versus RISPERIDONE for schizophrenia
Population: people with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
No significant clinical response ‐ short term (up to 6 months) CHLORPROMAZINE vs RISPERIDONE | RR 0.84 [0.53, 1.34] | 7 studies · 475 participants | Low Downgraded: risk of bias, imprecision, publication bias |
Mental state: short term (up to 6 months) BPRS endpoint scale score (high = poor) CHLORPROMAZINE vs RISPERIDONE | no estimate extracted | 4 studies · 247 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness, publication bias |
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) CHLORPROMAZINE vs RISPERIDONE | RR 1.7 [0.85, 3.4] | 3 studies · 235 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Quality of life: short term (up to 6 months) QOL endpoint scale score (high = good) CHLORPROMAZINE vs RISPERIDONE | no estimate extracted | 1 study · 100 participants | Very low Downgraded: risk of bias, imprecision, indirectness, publication bias |
Leaving the study early due to adverse effects ‐ short term (up to 6 months) CHLORPROMAZINE vs RISPERIDONE | RR 0.21 [0.01, 4.11] | 1 study · 41 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
CHLORPROMAZINE versus QUETIAPINE for schizophrenia
Population: people with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
No significant clinical response: short term (up to 6 months) CHLORPROMAZINE vs QUETIAPINE | RR 0.93 [0.81, 1.06] | 28 studies · 3241 participants | Moderate Downgraded: risk of bias |
Mental state: short term (up to 6 months) BPRS endpoint scale score (high = poor) CHLORPROMAZINE vs QUETIAPINE | no estimate extracted | 6 studies · 548 participants | Very low Downgraded: risk of bias, imprecision, indirectness, publication bias |
Quality of life: short term (up to 6 months) GQOL1‐74 endpoint scale score (high = good) CHLORPROMAZINE vs QUETIAPINE | no estimate extracted | 1 study · 59 participants | Very low Downgraded: risk of bias, imprecision, indirectness, publication bias |
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) CHLORPROMAZINE vs QUETIAPINE | RR 8.03 [4.78, 13.51] | 8 studies · 644 participants | Low Downgraded: risk of bias, imprecision, publication bias |
Leaving the study early due to any reason short term (up to 6 months) CHLORPROMAZINE vs QUETIAPINE | RR 1.04 [0.77, 1.41] | 12 studies · 1223 participants | Moderate Downgraded: risk of bias |